Evidence map›Paper›PMID 40026938›Full record

ReviewCureus2025

The Role of Machine Learning Models in Predicting Cirrhosis Mortality: A Systematic Review.

Khadija Abdikadir Mohamud, Suha Abdelhai Elzubair Eltahir, Hind AbdAlla Ahmed Alhardalo, Hadel Bakhet Albashir, Nora Qassem Alsyed Ali Mohamed Zain, Mohamed Elsayed Abdelrahman Ibrahim, Enas Nusreldeen Ahmed Fadlallah

Abstract readReview
In one paragraph

Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Khadija Abdikadir MohamudFaculty of Medicine, International University of Africa, Khartoum, SDN.
Suha Abdelhai Elzubair EltahirDepartment of Internal Medicine, Dr. Sulaiman Al Habib Medical Group Hospital, Buraydah, SAU.
Hind AbdAlla Ahmed AlhardaloDepartment of General Medicine, Abu Dhabi Health Services Company (SEHA) - Salma Rehabilitation Hospital, Abu Dhabi, ARE.
Hadel Bakhet AlbashirDepartment of General Medicine, Abu Dhabi Health Services Company (SEHA) - Salma Rehabilitation Hospital, Abu Dhabi, ARE.
Nora Qassem Alsyed Ali Mohamed ZainDepartment of General Practice, Abu Dhabi Health Services Company (SEHA) - Salma Rehabilitation Hospital, Abu Dhabi, ARE.
Mohamed Elsayed Abdelrahman IbrahimDepartment of Internal Medicine, Najran Armed Forces Hospital, Najran, SAU.
Enas Nusreldeen Ahmed FadlallahDepartment of Chemical Pathology, Aberdeen Royal Infirmary Foresterhill Health Campus, Aberdeen, GBR.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liver cirrhosis affects millions of individuals worldwide and is one of the primary causes of mortality. Early mortality prediction for cirrhosis patients may increase the possibility for medical professionals to treat the illness successfully. This study assesses the ability of machine learning (ML) models to predict cirrhosis mortality. We followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to search for relevant literature across four different databases. We found 379 studies of which 10 were eligible for inclusion in the current study. We analyzed 10 retrospective studies that showed that ML models outperformed conventional scores in predicting the death rate from end-stage liver disease (ESLD). Interestingly, models that used more parameters, such as patient demographics and extensive laboratory testing, exhibited higher prediction accuracy. With an area under the receiver operating characteristic (AUROC) ranging from 0.71 to 0.96, ML models showed consistently significant gains over traditional prognostic ratings. This review emphasizes how ML models might improve ESLD patient death prediction. Because machine learning models are more accurate than conventional approaches, it is important to incorporate data-driven informatics technologies into clinical settings. Additional validation and openness are required to guarantee model dependability and interpretability before ML may be used in clinical practice. The goal of future research should be to create reliable, interpretable models that may be used successfully in a variety of clinical contexts, enhancing ESLD patient treatment and results.

Indexed as

artificial intelligenceend-stage liver diseaseliver cirrhosismachine learningpredictive model

Identifiers

PMID40026938
PMCPMC11867977

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.